Tactile Systems Technology (NASDAQ:TCMD) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Key Points

• Tactile Systems Technology reported earnings of $0.14 per share, exceeding analyst expectations of $0.09 by $0.05.
• The company's updated guidance for fiscal year 2025 has not yet been announced in the report.
• Goldman Sachs Group Inc. increased its stake in Tactile Systems Technology by 2.1%, now holding approximately 0.80% of the company.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05, Zacks reports. Tactile Systems Technology had a return on equity of 8.41% and a net margin of 5.52%. Tactile Systems Technology updated its FY 2025 guidance to EPS.

Tactile Systems Technology Price Performance

Shares of TCMD traded up $0.24 during midday trading on Monday, reaching $9.89. The stock had a trading volume of 198,275 shares, compared to its average volume of 275,164. Tactile Systems Technology has a 52 week low of $8.61 and a 52 week high of $21.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.52 and a quick ratio of 3.99. The firm's 50 day moving average price is $10.06 and its 200-day moving average price is $12.69. The company has a market capitalization of $229.94 million, a P/E ratio of 14.98 and a beta of 0.96.

Insiders Place Their Bets

In related news, Director William W. Burke sold 3,300 shares of the company's stock in a transaction on Thursday, May 8th. The stock was sold at an average price of $9.67, for a total transaction of $31,911.00. Following the transaction, the director directly owned 48,520 shares of the company's stock, valued at approximately $469,188.40. The trade was a 6.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Elaine M. Birkemeyer sold 2,921 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $9.94, for a total value of $29,034.74. Following the completion of the transaction, the chief financial officer directly owned 99,111 shares in the company, valued at approximately $985,163.34. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tactile Systems Technology stock. Goldman Sachs Group Inc. grew its position in Tactile Systems Technology, Inc. (NASDAQ:TCMD - Free Report) by 2.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 186,936 shares of the company's stock after purchasing an additional 3,898 shares during the period. Goldman Sachs Group Inc. owned about 0.80% of Tactile Systems Technology worth $2,471,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 83.43% of the company's stock.

Wall Street Analysts Forecast Growth

TCMD has been the topic of several recent analyst reports. B. Riley raised Tactile Systems Technology to a "hold" rating in a research note on Wednesday, May 7th. Wall Street Zen downgraded Tactile Systems Technology from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Piper Sandler downgraded Tactile Systems Technology from an "overweight" rating to a "neutral" rating and cut their target price for the company from $25.00 to $14.00 in a research note on Tuesday, May 6th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, Tactile Systems Technology has a consensus rating of "Hold" and a consensus target price of $16.00.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.